- Home
- CHRO vs INDP Comparison
CHRO vs INDP Comparison
Compare CHRO & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRO
- INDP
- Stock Information
- Founded
- CHRO 2002
- INDP 2000
- Country
- CHRO United States
- INDP United States
- Employees
- CHRO N/A
- INDP N/A
- Industry
- CHRO
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- CHRO
- INDP Health Care
- Exchange
- CHRO Nasdaq
- INDP Nasdaq
- Market Cap
- CHRO 10.7M
- INDP 8.8M
- IPO Year
- CHRO 2024
- INDP N/A
- Fundamental
- Price
- CHRO $1.45
- INDP $0.50
- Analyst Decision
- CHRO Strong Buy
- INDP Strong Buy
- Analyst Count
- CHRO 1
- INDP 2
- Target Price
- CHRO N/A
- INDP $8.50
- AVG Volume (30 Days)
- CHRO 8.2K
- INDP 1.2M
- Earning Date
- CHRO 03-27-2025
- INDP 03-13-2025
- Dividend Yield
- CHRO N/A
- INDP N/A
- EPS Growth
- CHRO N/A
- INDP N/A
- EPS
- CHRO N/A
- INDP N/A
- Revenue
- CHRO N/A
- INDP N/A
- Revenue This Year
- CHRO N/A
- INDP N/A
- Revenue Next Year
- CHRO N/A
- INDP N/A
- P/E Ratio
- CHRO N/A
- INDP N/A
- Revenue Growth
- CHRO N/A
- INDP N/A
- 52 Week Low
- CHRO $0.45
- INDP $0.47
- 52 Week High
- CHRO $3.80
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- CHRO 43.38
- INDP 24.26
- Support Level
- CHRO $1.34
- INDP $0.58
- Resistance Level
- CHRO $2.00
- INDP $0.78
- Average True Range (ATR)
- CHRO 0.17
- INDP 0.14
- MACD
- CHRO -0.02
- INDP -0.03
- Stochastic Oscillator
- CHRO 16.58
- INDP 1.89
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.